SQLite Web: event_store.db

Update row sig_839760354bd4 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","company":"Trevi Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_44fde3570732dfde","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:17:29.587651+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt","source_event_id":"evt_440ad756e222","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"75da3564a078aa44","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-21","2026-04-22","2026-04-23","2026-04-06","2026-06-03","2029 Annual Meeting of Stockholders","December 31, 2025","December 31, 2026"],"entities":[{"asset_class":"equity","name":"Trevi Therapeutics, Inc.","relevance":"high","symbol":"TRVI","type":"issuer"},{"asset_class":"other","name":"Ernst & Young LLP","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"other","name":"VirtualShareholderMeeting.com","relevance":"medium","symbol":"","type":"meeting_platform"},{"asset_class":"other","name":"proxyvote.com","relevance":"medium","symbol":"","type":"proxy_voting_site"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal text (no prior filing comparison content included).","The specific director nominee name and any detailed executive compensation or plan terms are not included in the provided excerpt.","The exact SEC filing timestamp/date beyond the provided filing_date field is not shown in the excerpt.","The proxy statement amendment number and whether it is an initial filing or amendment (Amendment No. blank) are not specified in the excerpt."],"key_facts":["Form DEF 14A is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.","Trevi Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders exclusively online as a virtual web conference.","The annual meeting is scheduled for Wednesday, June 3, 2026 at 11:00 a.m. Eastern Time.","Stockholders who owned common stock at the close of business on April 6, 2026 (record date) can vote.","At the meeting, stockholders will consider and vote on: (1) election of one Class I director until the 2029 Annual Meeting; (2) ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026; (3) advisory approval of compensation paid to named executive officers; (4) approval of the Trevi Therapeutics, Inc. Amended and Restated 2019 Stock Incentive Plan; (5) approval of an amendment to increase authorized common shares from 200,000,000 to 400,000,000; (6) other business properly brought before the meeting.","The meeting will be conducted without a physical location; stockholders cannot attend in person.","The proxy materials are available online and a Notice of Internet Availability is planned to be mailed on or about April 23, 2026 to stockholders of record as of April 6, 2026.","The Board recommends voting in favor of the director nominee (proposal 1) and in favor of proposals 2, 3, 4, and 5."],"numeric_claims":[{"label":"Annual meeting date","value":"2026-06-03"},{"label":"Annual meeting time (ET)","value":"11:00 a.m. Eastern Time"},{"label":"Record date","value":"2026-04-06"},{"label":"Authorized common shares (current)","value":"200,000,000"},{"label":"Authorized common shares (proposed)","value":"400,000,000"},{"label":"Fiscal year ending","value":"2026-12-31"},{"label":"Notice mailing timing","value":"on or about April 23, 2026"}],"primary_claim":"Trevi Therapeutics, Inc. filed Form DEF 14A for its 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026, with stockholder votes on six specified proposals.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Trevi Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing outlines virtual meeting logistics and six matters stockholders will vote on, including director election, auditor ratification, executive compensation (advisory), equity plan approval, and an increase in authorized common shares.","topics":["SEC filing","proxy statement","annual meeting","corporate governance","auditor ratification","executive compensation","stock incentive plan","authorized shares increase","virtual meeting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Trevi Therapeutics, Inc. \u00b7 Filed 20260421","ticker":"TRVI","tickers":["TRVI"],"title":"TRVI filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166695.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel